Search clinical trials for: travoprost 0.003%

Total 383 results

Summa Health System

Completed

The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye

Glaucoma | Application Site Pigmentation Changes

United States
Innovative Medical

Completed

Diurnal Curves With Bimatoprost 0.03% Versus Travoprost 0.004%

Glaucoma

United States
Allergan

Completed

Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)

Ocular Hypertension | Open-Angle Glaucoma

United States
Alcon Research

Completed

Travoprost 3-Month Safety and Efficacy Study

Ocular Hypertension | Open-Angle Glaucoma
Alcon Research

Completed

A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma

Ocular Hypertension | Glaucoma, Angle-Closure

United States, Australia
Allergan

Completed

Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues

Ocular Hypertension | Open Angle Glaucoma

United States
University Hospital, Basel, Switzerland

Completed

Influence of Prostaglandins on Ocular Blood Flow in Glaucoma Patients

Open-Angle Glaucoma

Switzerland
Aerie Pharmaceuticals

Completed

AR-12286 Fixed Dose Combination to Lower Elevated Intraocular Pressure

Ocular Hypertension | Glaucoma

United States
Semmelweis University

Completed

Continuous Intraocular Pressure (IOP) Measurement and Ability to Detect Treatment Effect

Ocular Hypertension | Glaucoma

Hungary
Alcon Research

Completed

Divided Dose of TRAVATAN®

Ocular Hypertension | Open-angle Glaucoma
Allergan

Completed

Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%

Ocular Hypertension | Glaucoma

United States
Alcon Research

Completed

Travoprost Five Day Posology Study

Ocular Hypertension | Open-angle Glaucoma (OAG)

United States
Kasr El Aini Hospital

Completed

Comparison Between Latanoprost , Travoprost and Tafluprost in Reducing IOP Fluctuation in POAG Patients

Primary Open Angle Glaucoma

Egypt
Alcon Research

Terminated

Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)

Intraocular Pressure

United States
Alcon Research

Completed

Efficacy Study of Travoprost APS Versus TRAVATAN

Ocular Hypertension | Open Angle Glaucoma
Alcon Research

Completed

Phase III Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients

Ocular Hypertension | Open-angle Glaucoma
Alcon Research

Completed

Effects of Travatan Z and Xalatan on Ocular Surface Health

Ocular Hypertension | Glaucoma
Alcon Research

Completed

Efficacy of Changing to TRAVATAN® From Prior Therapy

Ocular Hypertension | Open-Angle Glaucoma
Alcon Research

Completed

Safety and Intraocular Pressure (IOP) Lowering Efficacy of Low Dose Travoprost

Ocular Hypertension | Open-angle Glaucoma

United States
BioMarin Pharmaceutical

Completed

Dose-Finding Study to Evaluate the Safety, Efficacy, & Tolerability of Multiple Doses of rAvPAL-PEG in Subjects With PKU

Phenylketonuria

United States
Alcon Research

Completed

Efficacy of Changing to TRAVATAN® From Prior Therapy

Ocular Hypertension | Open-angle Glaucoma
Laboratorios Sophia S.A de C.V.

Completed

Safety and Tolerability of the Ophthalmic Solution PRO-179 Compared With Travatan® (PRO-179/I)

Glaucoma

Mexico
Alcon Research

Completed

Travatan Z in Ocular Surface Health in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-angle Glaucoma
Allergan

Completed

Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma, Open-Angle

Canada, United States
Alcon Research

Completed

Examination of Ocular Surface Effects With Administration of Travatan Z and XALATAN

Ocular Hypertension | Open-angle Glaucoma
Alcon Research

Completed

A Single Dose Comfort Comparison of Travatan Z in One Eye Versus Xalatan in the Opposite Eye in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma
Alcon Research

Completed

Phase III Clinical Trial of TRAVATAN Z in Ocular Surface Health

Ocular Hypertension | Open-angle Glaucoma
Alcon Research

Completed

Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients

Ocular Hypertension | Glaucoma
Alcon Research

Completed

A 12-Month Study to Evaluate the Efficacy and Safety of Once-Daily Instillation of Combination Glaucoma Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma, Open-angle

Belgium
Lee's Pharmaceutical Limited

Suspended

Antiplatelet Thrombolysin (Anfibatide) Phase 1 Clinical Trial in Healthy Volunteers

Antiplatelet Drug

China
Alcon Research

Completed

Investigation of Intraocular Pressure (IOP) Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension Glaucoma

Ocular Hypertension | Normal Tension Glaucoma

Japan
Innovative Medical

Completed

Bimatoprost Monotherapy vs. Dual Therapy With Travoprost and Timolol in Patients With Glaucoma and Ocular Hypertension

Glaucoma

United States
Assiut University

Unknown

Effect Of Topical Prostaglandin F2α Analogs,Fractional CO2 Laser, Excimer Laser Or Their Combination In Treatment Of Vitiligo

Vitiligo | Excimer Laser | Fractional CO2 Laser
Alcon Research

Completed

A 6-Week Safety and Efficacy Study of Travatan Compared to Xalcom in Subjects With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)

Ocular Hypertension | Glaucoma, Open-Angle

United States
Alcon Research

Terminated

Study of TRAVATAN in Subjects With Iris Pigmentation Changes

Ocular Hypertension | Open-Angle Glaucoma
Alcon Research

Withdrawn

Three Month Safety and Efficacy Study of TRAVATAN® Versus Travoprost Ophthalmic Solution, 0.004%

Ocular Hypertension | Open Angle Glaucoma
United States Air Force
Alcon Research

Completed

Dry Eye and Irritation Comparison of Latanoprost With the Preservative Versus Travoprost Without Preservative

Ocular Hypertension | Open-Angle Glaucoma | Ocular Dryness | Ocular Irritation

United States
Alcon Research

Completed

Travoprost New Formulations in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-angle Glaucoma
Eisai Inc.

Completed

Paired-Comparison Study Evaluating the Efficacy and Safety of E6201 Versus Vehicle for the Treatment of Plaque-Type Psoriasis

Chronic Plaque Psoriasis

United States
Alcon Research

Completed

Travoprost 0.004%/Timolol 0.5% Versus Latanoprost 0.005%/Timolol in Chinese Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-angle Glaucoma

China
Alcon Research

Terminated

A Multicenter Study of the Pigmentation in the Trabecular Meshwork After Two Years of Treatment With TRAVATAN 0.004% Ophthalmic Solution

Open-angle Glaucoma
Alcon Research

Completed

A Phase III Study of Travoprost/Timolol Combination in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma
Alcon Research

Completed

Safety and Efficacy of Travoprost/Timolol BAC-free

Ocular Hypertension | Open-Angle Glaucoma

Japan
Alcon Research

Completed

An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®

Ocular Hypertension | Glaucoma
Aerie Pharmaceuticals

Completed

Ocular Hypotensive Efficacy of AR-102

Glaucoma

United States
Alcon Research

Completed

Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension Patients

Ocular Hypertension | Open-angle Glaucoma
Alcon Research

Completed

A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-angle Glaucoma

United States
Alcon Research

Completed

Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension

Glaucoma
Aerie Pharmaceuticals

Completed

A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days

Ocular Hypertension | Open Angle Glaucoma

United States
Alcon Research

Completed

Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)

Ocular Hypertension | Glaucoma | Open-Angle Glaucoma

3

Subscribe